Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. The Boston biotech scene’s a mess, and Marty Makary’s and Jay Bhattacharya’s nominations have been advanced to the full Senate for FDA and NIH leadership. Also, we see another company testing GLP-1s for alcohol use disorder.

Read the rest…